Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00202774
Status:
COMPLETED
Last Update Posted:
2023-04-12
First Post:
2005-09-12
Brief Title:
Safety and Efficacy Study of XELOX vs Oxaliplatin5-FU CI as First Line Treatment in Metastatic Colorectal Cancer
Sponsor:
Spanish Cooperative Group for the Treatment of Digestive Tumours TTD
Organization:
Spanish Cooperative Group for the Treatment of Digestive Tumours TTD
Study Overview
Official Title:
Phase III Multicenter Ramdomised Open-label Study to Evaluate the Safety and Efficacy of Combination Therapy With XELOX vs Oxaliplatin and 5-FU CI as First Line Treatment in Advanced or Metastatic Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2019-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine time to disease progression of combination therapy with capecitabine and oxaliplatin XELOX vs oxaliplatin and 5-fluorouracil in continous infusion 5-FU CI as first line treatment in advanced or metastatic colorectal cancer
Detailed Description:
The purpose of this study is to determine time to disease progression of combination therapy with capecitabine and oxaliplatin XELOX vs oxaliplatin and 5-fluorouracil in continous infusion 5-FU CI as first line treatment in advanced or metastatic colorectal cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None